¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"infection control study"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® cohort study ÇÑ±Û °èȹ¿¬±¸, ÀüÇ⿬±¸, ¾Õ¹æÇ⿬±¸
¼³¸í   
  ºÐ¼®¿ªÇп¡¼­ÀÇ ¿äÀÎ-´ëÁ¶¿¬±¸ÀÇ ÇÑ ±â¹ýÀÌ´Ù. »ç¶÷ÀÇ Áý´Ü¿¡¼­ Áúº´À¯Çà°ú °¡¼³¿äÀΰúÀÇ ¿¬°ü¼ºÀ» °íÂûÇÏ¿© Àΰú°ü°è¸¦ ¹àÈ÷´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÑ´Ù. °¡¼³¿äÀÎÀ» °®´Â Áý´Ü°ú °®Áö ¾Ê´Â Áý´Ü, È¤Àº ÀûÀº Áý´Ü°ú ¸¹Àº Áý´ÜÀÇ 2±º(ÄÚȣƮ)À¸·Î ³ª´©¾î ÃßÀû Á¶»çÇÏ¿© °¢ Áý´Ü¿¡¼­ÀÇ Áúº´ÀÇ ¹ß»ýºóµµ¸¦ ºñ±³Çϴ °ÍÀÌ´Ù. ÀϹÝÀûÀ¸·Î´Â ÀüÇâÀûÀΠ¿¬±¸·Î ÇàÇØÁö´Â °æ¿ì°¡ ¸¹À¸³ª ÈÄÇâÀûÀΠ¿¬±¸·Îµµ ÇàÇÏ¿©Áø´Ù.
¿µ¹® quality control ÇÑ±Û Á¤µµ°ü¸®, ǰÁú°ü¸®, Áú°ü¸®
¼³¸í   
  °úÇÐÀû ¿ø¸®¸¦ ÀÀ¿ëÇÏ¿© Á¦Ç°Ç°ÁúÀÇ À¯Áö-Çâ»óÀ» ±âÇϱâ À§ÇÑ °ü¸®. ³ÐÀº ¶æÀ¸·Î´Â °¡Àå ½ÃÀ强ÀÌ ³ôÀº Á¦Ç°À» °¡Àå °æÁ¦ÀûÀ¸·Î »ý»êÇϱâ À§ÇÑ ÀÏ·ÃÀǠü°ÔÀû Á¶Ä¡¸¦ °¡¸®Å°³ª, ÀϹÝÀûÀ¸·Î´Â ¾ÕÀÇ Á¼Àº ¶æÀÇ ÇØ¼®ÀÌ Åë¿ëµÈ´Ù. ÃʱâÀÇ QC´Â ÀüÁ¦Ç°¿¡ ´ëÇØ Ä¡¼ö-Áß·®-üÀûÀ̳ª Àç·áÀÇ È­ÇÐÀû ¼ººÐ µîÀ» ÃøÁ¤Çϰí, ±×°ÍÀ» ¹Ì¸® Á¤ÇØ ³õÀº Ç°ÁúÇ¥Áذú ºñ±³ÇÏ¿© ÀûºÎ¸¦ ÆÇÁ¤Çϴ ¹æ¹ýÀÌ ÃëÇØÁ³´Ù.
¿µ¹® infection ÇÑ±Û °¨¿°
¼³¸í   
  º´¿ø¹Ì»ý¹°ÀÌ »ç¶÷À̳ª µ¿¹° ¶Ç´Â ½Ä¹°ÀÇ Á¶Á÷. Ã¼¾×-Ç¥¸é¿¡ Á¤ÂøÇÏ¿© Áõ½ÄÇϴ »óÅÂ. ÀÌ °æ¿ì µ¿¹° ¶Ç´Â ÀÎü¿¡ ¿©·¯ °¡Áö Áõ»ó, Áï Áúº´À» ÀÏÀ¸Å°´Â °æ¿ì¿Í ÀÏÀ¸Å°Áö ¾Ê´Â °æ¿ì°¡ ÀÖ´Ù. ¿¹¸¦ µé¸é, ÀϺ»³ú¿°¹ÙÀÌ·¯½º°¡ ÀÎü¿¡ Ä§ÀÔÇÏ¿© Ã¼³»¿¡ Áõ½ÄÇϸ頾 »ç¶÷¿¡°Ô´Â °í¿­-µÎÅë-ÀǽÄÀå¾Ö-°æ·Ã µîÀÇ Áõ»óÀÌ ÀϾ ¹ßº´À» ¾ËÁö¸¸, ´ë´Ù¼öÀÇ »ç¶÷Àº Ã¼³»¿¡¼­ ¹ÙÀÌ·¯½º°¡ Áõ½ÄÇÏ´õ¶óµµ Áõ¼¼ÀÇ Á¤µµ°¡ ³·°í ¹ß¿­À̳ª ±× ¹ÛÀÇ Áõ¼¼µµ ¾ø¾î °¨¿°À» ¸ð¸¥´Ù. À̿͠°°ÀÌ º´¿ø¹Ì»ý¹°Àº ÀÎü¿¡ °¨¿°µÇ´õ¶óµµ ¹ßº´Çϴ °æ¿ì¿Í ÇÏÁö ¾Ê´Â °æ¿ì°¡ ÀÖ´Ù. ÀüÀÚ¸¦ Áõ»ó°¨¿°, ÈÄÀÚ¸¦ ¹«Áõ»ó°¨¿°À̶ó ÇÑ´Ù. °¨¿°ÀÇ ±Ù¿øÀÌ µÇ´Â È¯ÀÚ-º¸±ÕÀÚ-°¨¿°µ¿¹°-¸Å°³µ¿¹°-º´¿øÃ¼¸¦ Æ÷ÇÔÇÑ ¹è¼³¹° ¹× ±×¿¡ ÀÇÇØ °¨¿°µÈ °ÍÀ» °¨¿°¿øÀ̶ó Çϰí, ÀÌ·¯ÇÑ °¨¿°¿ø¿¡¼­ Á÷Á¢ ¶Ç´Â °£Á¢À¸·Î »ýü¿¡ º´¿øÃ¼°¡ Ä§ÀÔÇϴ °æ·Î¸¦ °¨¿°°æ·Î¶ó ÇÑ´Ù. °¨¿°°æ·Î¿¡´Â °ø±â°¨¿°-Á¢Ã˰¨¿°-°æ±¸°¨¿°-°æÇǰ¨¿° µîÀÌ ÀÖ´Ù. ¶ÇÇÑ °¨¿°ÁõÀº Àü¿°¼º°ú ºñÀü¿°¼ºÀÇ µÎ °¡Áö·Î ³ª´­ ¼ö ÀÖ´Ù. ÀüÀڴ Áúº´ÀÇ °æ°ú Áß¿¡(¶§·Î´Â Àẹ±â³ª È¸º¹±â¿¡) °¨¿°ÇÑ »ýüÀÇ ºÐºñ¹° ¶Ç´Â ¹è¼³¹°°ú ÇÔ²² º´¿øÃ¼°¡ ³ª¿Í¼­ Á¢ÃË ¶Ç´Â ¸Å°³¿¡ ÀÇÇØ ´Ù¸¥ °³Ã¼¸¦ °¨¿°½Ã۴ °æ¿ì¸¦ ¸»ÇÑ´Ù. ¸¶¸¶-µðÇÁÅ׸®¾Æ-¼ºÈ«¿­-Æä½ºÆ®-ÄÝ·¹¶ó-ÀÌÁú µîÀÌ ÀÌ¿¡ ¼ÓÇÑ´Ù. ÈÄÀڴ º´¿øÃ¼°¡ °¨¿°ÇÑ »ýü¿¡¼­ ¹è¼³µÇÁö ¾Ê°Å³ª ¹è¼³µÇ´õ¶óµµ ´Ù¸¥ °³Ã¼¿¡´Â °¨¿°À» ÀÏÀ¸Å°Áö ¾Ê´Â °ÍÀ¸·Î ¿©±â¿¡´Â ÆÄ»ódz-¸»¶ó¸®¾Æ-¹ßÁøÆ¼Çª½º-»êÈÄ¿­ µîÀÌ ÀÖ´Ù.
¿µ¹® droplet infection ÇÑ±Û ºñ¸»°¨¿°, ÀÛÀº¹æ¿ï°¨¿°
¼³¸í   
  º¸±ÕÀÚ³ª Áõ»óÀÌ Àִ ȯÀڠȤÀº À̹̠°¨¿°µÇ¾î Àִ »ç¶÷ÀǠȣÈí¿¡¼­ ³ª¿Â Á÷°æ 10¸¶ÀÌÅ©·Ð ¶Ç´Â ±× ÀÌÇÏÀÇ ¾×üÀÔÀÚ¿¡ ºÎÀ¯Çϰí Àִ º´¿øÃ¼ÀÇ ÈíÀÔ¿¡ ÀÇÇѠȣÈí±â°¨¿°À» À̸¥´Ù. ÀÎÇ÷翣ÀÚ³ª Æíµµ¿°°ú °°À̠ȯÀÚ°¡ ±âħÀ» Çϰųª ´ëÈ­ µµÁß¿¡ ÀÚÀßÇÑ ºñ¸»°ú ÇÔ²² º´¿ø±ÕÀÌ °ø±â¿Í ÇÔ²² º´¿ø±ÕÀÌ ¹æÃâµÇ¾î °ø±â¿Í ÇÔ²² È£Èí±â·Î ÈíÀÔµÊÀ¸·Î½á °¨¿°µÇ´Â °ÍÀ» ¸»ÇÑ´Ù. °áÇÙ-À¯Ç༺°¨±â-¹éÀÏÇØ-µðÇÁÅ׸®¾Æ-Æó·Å µîÀÌ ÀÌ¿¡ ÀÇÇÏ¿© ÀüÆÄµÈ´Ù.
¿µ¹® wound infection ÇÑ±Û »ó󰨿°
¼³¸í   
  Àý¼Õ µîÀÇ ±â°èÀû »óÇØ, ÀÎÀ§Àû ºÎ»ó ¶Ç´Â Å¸±ÕÀǠħÀÔ¿¡ ÀÇÇØ »óó³­ Á¶Á÷¿¡¼­ Ä§ÀÔÇÏ¿© °¨¿°½Ã۴ °Í.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • case-control study
    ȯÀÚ´ëÁ¶±º¿¬±¸, »ç·Ê´ëÁ¶±º¿¬±¸
  • hospital infection control
    º´¿ø°¨¿°°ü¸®
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • laboratory infection control
    °Ë»ç½Ç°¨¿°°ü¸®
  • nosocomial infection control
    º´¿ø³»°¨¿°°ü¸®
  • air study
    °ø±âÁÖÀÔ°Ë»ç
  • cohort study
    ÄÚȣƮ¿¬±¸, ÄÚȣƮÁ¶»ç
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
  • crossover study
    ±³Â÷¿¬±¸
  • cross-sectional study
    ´Ü¸é¿¬±¸
  • case comparison study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case referent study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case study
    Áõ·Ê¿¬±¸, »ç·ÊÁ¶»ç
  • diachronic study
    ºñµ¿½Ã¿¬±¸
  • double blind study
    ÀÌÁ߸Ͱ˿¬±¸
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • case-control study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • control
    1. ÅëÁ¦, Á¦¾î, 2. ´ëÁ¶, 3. °ü¸®
  • quality control
    Á¤µµ°ü¸®, ǰÁú°ü¸®, Áú°ü¸®
  • reflex control
    ¹Ý»çÁ¶Àý
  • safety control
    ¾ÈÀü°ü¸®
  • sugar control
    Ç÷´çÁ¶Àý
  • impulse control disorder
    Ãæµ¿Á¶ÀýÀå¾Ö, Ãæµ¿Á¶Àýº´
  • study design
    ¿¬±¸¼³°è
  • study
    ¿¬±¸, °Ë»ç, Á¶»ç
  • arterial blood gas study
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • cohort study
    ÄÚȣƮ¿¬±¸
  • cross-sectional study
    ´Ü¸éÁ¶»ç¿¬±¸
  • ecological study
    »ýÅ¿¬±¸
  • longitudinal study
    ÃßÀû¿¬±¸
  • observational study
    °üÂû¿¬±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • infection control study
    °¨¿°°ü¸®Á¶»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • case-control study
    (¢¡retrospective) ÈÄÇ⿬±¸, µÞ¹æÇ⿬±¸
  • hospital infection control
    º´¿ø°¨¿°°ü¸®
  • laboratory infection control
    °Ë»ç½Ç°¨¿°°ü¸®
  • nosocomial infection control
    ¿ø³»°¨¿°°ü¸®
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • air study
    °ø±âÁÖÀÔ°Ë»ç
  • arterial blood gas study
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • cardiac gated MR study
    ½ÉÀ嵿±âÀÚ±â°ø¸í°Ë»ç
  • case study
    Áõ·Ê¿¬±¸
  • case comparison study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case compeer study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case referent study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case-base study
    ȯÀÚ¸ðÁý´Ü¿¬±¸
  • cohort study
    (¢¡prospective) °èȹ¿¬±¸, ÀüÇ⿬±¸, ¾Õ¹æÇ⿬±¸
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • infection control study
    °¨¿°°ü¸®¿¬±¸
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hospital infection control
    ¿ø³»<º´¿ø>°¨¿°°ü¸®
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • B cell study
    B ¼¼Æ÷°Ë»ç
  • air study
    °ø±â(ÁÖÀÔ) °Ë»ç(¹ý)
  • arterial blood gas study
    µ¿¸ÆÇ÷ °¡½ººÐ¼®
  • phase 1 study
    ÀÓ»óÁ¦1»ó½ÃÇè.
  • pilot study
    ¿¹ºñ½ÇÇè.
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀüÀÓ»ó½ÃÇè(îñìúßÉãËúÐ).
  • pressure flow study
    ¾Ð·ù·® Á¶»ç
  • pressure-perfusion study
    ¾Ð·Â°ü·ù°Ë»ç
  • prospective study
    °èȹÀû¿¬±¸, ÀüÇâÀû¿¬±¸
  • real time study
    ½Ç½Ã°£ °Ë»ç
  • AGC (automatic gain control)
    ÀÚµ¿ °ÔÀÎ Á¶Àý
  • AGC (automatic gain control)
    ÀÚµ¿ (í»ÔÑ) °ÔÀÎ Á¶Àý (ðàï½), À̵æÀÚµ¿Á¶Àý
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • infection control study
    °¨¿°°ü¸®¿¬±¸
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • case control study
    ȯÀÚ´ëÁ¶¿¬±¸.
  • nested case control study
  • hospital infection control
    ¿ø³»<º´¿ø>°¨¿°°ü¸®
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • laboratory infection control
    °Ë»ç½Ç°¨¿°°ü¸®
  • nosocomial infection control
    ¿ø³»°¨¿°°ü¸®
  • air study
    °ø±â(ÁÖÀÔ) °Ë»ç(¹ý)
  • arterial blood gas study
    µ¿¸ÆÇ÷ °¡½ººÐ¼®
  • cardiac gated MR study
    ½ÉÀ嵿±â ÀÚ±â°ø¸í °Ë»ç
  • case study
    Áõ·Ê¿¬±¸(Áõ¿¹¿¬±¸).
  • case study
    Áõ·Ê¿¬±¸(ñøçÓæÚϼ).
  • cohort study
    ÄÚ¿ÀÆ®¿¬±¸(ÊÙËçË´), Æø·ÎºñÆø·Î¿¬±¸.
  • controlled clinical study
    (Ãß°èÇÐÀû) °ü¸®È­(Ì§Ë­Ì°ËøË´ËöÌ´)(ÀÓ»ó)½ÃÇè( ËöË×ËàÌ´).
  • double-blind study
    ÀÌÁ߸ͰË.
  • family study
    °¡Á·Á¶»ç(¿¬±¸)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Abnormality by infection
    °¨¿°±âÇü
    [¿¾ ¿ë¾î] °¨¿°ºñÁ¤»ó
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • insect control
    °ïÃæ±¸Á¦, °ïÃæ¹æÁ¦
  • congenital infection
    ¼±Ãµ°¨¿°
  • ectopic infection
    À̼Ұ¨¿°
  • helminthic infection
    ¿¬Ãæ°¨¿°
  • household infection
    Áý¾È°¨¿°
  • indigenous infection
    ÅäÂø°¨¿°
  • infection intensity
    °¨¿°°­µµ
  • latent infection
    Àẹ°¨¿°
  • Leishmania mexicana mexicana infection
    ¸ß½ÃÄÚ¸®½´¸¸Æí¸ðÃæÁõ
  • mosquito borne infection
    ¸ð±â¸Å°³°¨¿°
  • opportunistic infection
    ±âȸ°¨¿°
  • oral infection
    °æ±¸°¨¿°
  • percutaneous infection
    °æÇǰ¨¿°
  • primary infection
    ÀÏÂ÷°¨¿°
  • protozoan infection
    ¿øÃæ°¨¿°
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blance study
    ±ÕÇü¿¬±¸(гû¬æÚϼ)
  • abortive infection
    ¹Ì¼÷°¨¿° (Ú±âÙÊïæø)
  • abortive infection
    ºÎÀü°¨¿° (ÜôîïÊïæø)
  • abortive infection
    ºÒ¿Ï°¨¿° (ÝÕèÇÊïæø)
  • cross-infection
    ±³Â÷°¨¿°(Îßó©Êïæø)
  • endosymbiotic infection
    ³»°ø»ý °¨¿° (Ò®ÍìßæÊïæø)
  • latent infection
    Àẹ°¨¿°(íÖÜÑÊïæø)
  • localized infection
    ±¹¼Ò°¨¿°(ÏÑá¶Êïæø)
  • productive infection
    »ý»ê °¨¿°(ßæß§Êïæø)
  • acceptor control
    ¼ö¿ëü Á¦¾î (â¥é»ô÷ ð¤åÙ)
  • acceptor-control ratio
    ¼ö¿ëü Á¦¾îÀ² (â¥é»ô÷ ð¤åÙëÒ)
  • adenylate control hypothesis
    ¾Æµ¥´Ò»ê(ß«)Á¶Àý¼³(ðàï½àã)
  • autogenous control
    ÀÚÀÎÁ¶Àý (í»ì×ðàï½)
  • control
    "´ëÁ¶(ÓßðÎ), Á¶Àý(ðàï½), Á¦¾î(ð¤åÙ)"
  • control analysis
    ´ëÁ¶ ºÐ¼®(ÓßðÎÝÂà°)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • air study
    °ø±â(ÁÖÀÔ)°Ë»ç(¹ý)
  • cardiac gated MR study
    ½ÉÀ嵿±âÀÚ±â°ø¸í°Ë»ç
  • pilot study
    ¿¹ºñ½ÇÇè
  • prospective study
    ÀüÇâÀû¿¬±¸
  • real time study
    ½Ç½Ã°£°Ë»ç
  • retrospective study
    ÈÄÇ⼺¿¬±¸
  • study of choice
    ÃÖ¼±ÀÇ °Ë»ç
  • AGC [=automatic gain control]
    ÀÚµ¿°ÔÀÎÁ¶Àý
  • control
    ´ëÁ¶, Á¶Àý, Á¦¾î, °ü¸®, ±ÔÁ¦, ¹æÁ¦
  • control group
    ´ëÁ¶±º
  • equipment quality control
    ÀåÄ¡ÀÇ ¼º´É°ü¸®
  • pulse control unit
    ¸Æ¹ÚÁ¶Àý´ÜÀ§
  • quality control
    È­Áú°ü¸®, ǰÁú°ü¸®
  • remote control
    ¿ø°ÝÁ¶Á¾, ¿ø°ÝÁ¶ÀÛ
  • time gain control
    ½Ã°£°ÔÀÎÁ¶Àý
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SENIC study of the efficacy of nosocomial infection control
CRI Cardiac Risk Index; catheter-related infection; chronic renal insufficiency; chronic respiratory ins...
APIC Association for Practitioners in Infection Control
IC icteric, icterus; immune complex; immunoconjugate; immunocytochemistry; immunocytotoxicity; impedanc...
ICP incubation period; indwelling catheter program; infantile cerebral palsy; infection-control practiti...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SENIC Study of the Efficacy of Nosocomial Infection Control
HICPAC Hospital Infection Control Practice Advisory Committee
ICP Infection Control Practitioner
IC Infection control
ICN infection control nurse
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • case control study
    ȯÀÚ ´ëÁ¶ ¿¬±¸
  • air study
    °ø±â °Ë»ç, °ø±â ÁÖÀÔ °Ë»ç, °ø±â °Ë»ç¹ý, °ø±â ÁÖÀÔ °Ë»ç¹ý
  • arterial blood gas study
    µ¿¸ÆÇ÷ °³½º ºÐ¾Ð ÃøÁ¤
  • case study
    Áõ·Ê ¿¬±¸
  • coagulation study
    ÀÀ°í °Ë»ç
  • controlled clinical study
    °ü¸®È­ ½ÃÇè, °ü¸®È­ ÀÓ»ó ½ÃÇè, Ãß°èÇÐÀû °ü¸®È­ ½ÃÇè, Ãß°èÇÐÀû °ü¸®È­ ÀÓ»ó ½ÃÇè
  • cross-sectional study
    Ⱦ´Ü ¿¬±¸¹ý, Ⱦ´Ü Á¶»ç¹ý
  • double-blind study
    ÀÌÁß ¸Í°Ë ¿¬±¸
  • electroencephalographic study
    ³úÆÄ °Ë»ç
  • enzyme marker study
    È¿¼Ò Ç¥Áö ¿¬±¸
  • longitudinal study
    ´©³âÀû ¿¬±¸, Á¾Àû ¿¬±¸, Á¾´Ü ¿¬±¸¹ý
  • microbiologic study
    »ý¹°ÇÐÀû °Ë»ç
  • microinjection study
    ¹Ì¼¼ ÁÖ»ç ¿¬±¸
  • mounted study cast
    ºÎÂøµÈ Áø´Ü ¸ðÇü
  • neurophysiological study
    ½Å°æ »ý¸®ÇÐÀû ¿¬±¸
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
case-control study <epidemiology> A study in which the risk factors of people with a disease are compared with those without a disease.
It is an epidemiological method that begins by identifying persons with the disease or condition of interest (the cases) and compares their past history of exposure to identified or suspected risk factors with the past history of similar exposures among persons who resemble the cases but do not have the disease or condition of interest (the controls).
The relationship of an attribute to the disease can therefore be examined by comparing affected and non-affected individuals with regard to the frequency or levels of the attribute in each group.
(05 May 2002)
infection control Programs of disease surveillance, generally within health care facilities, designed to investigate, prevent, and control the spread of infections and their causative microorganisms.
(12 Dec 1998)
infection control, dental Efforts to prevent and control the spread of infections within dental health facilities or those involving provision of dental care.
(12 Dec 1998)
infection control nurse A registered nurse with additional education in the monitoring and prevention of nosocomial infections in the client population in an agency.
Synonym: infection control nurse.
(05 Mar 2000)
infection control practitioners Physicians or other qualified individuals responsible for implementing and overseeing the policies and procedures followed by a health care facility to reduce the risk of infection to patients and staff.
(12 Dec 1998)
analytic study In epidemiology, a study designed to examine associations, commonly putative or hypothesised causal relationships; usually concerned with identifying or measuring the effects of risk factors or with the health effects of specific exposures.
(05 Mar 2000)
blinded study Clinical trials of drugs are often done blinded so that the patient does not know (is blinded as to) whether they are receiving the product being tested or the control/placebo to ensure that the results of a study are not affected by a possible placebo effect (by the power of suggestion).
(12 Dec 1998)
blind study A study in which the experimenter is unaware of which group is subject to which procedure.
(05 Mar 2000)
retrospective study <epidemiology> A study in which people are enrolled and then have their history of risks, infections or disease measured.
(05 Dec 1998)
rosenzweig picture-frustration study A projective test depicting cartoon-like characters in frustrating situations. The scoring of the subject's responses indicates the direction of hostility or aggression, that is, whether he blames himself, the other person, or the set of circumstances.
(12 Dec 1998)
cohort study A study using epidemiological methods, such as a clinical trial, in which a cohort with a particular attribute (e.g., smokers, recipients of a drug) is followed prospectively and compared for some outcome (e.g., disease, cure) with another cohort not possessing the attribute.
(05 Mar 2000)
pioped study <radiology> 251 patients with documented PE on pulmonary angiograms were given V/Q scans: 102 high probability, 105 intermediate probability, 39 low probability, 5 normal or near-normal
(12 Dec 1998)
multicenter study A controlled study executed by several cooperating institutions.
(12 Dec 1998)
multigeneration study Toxicity test in which at least 3 generations of the test organisms are exposed to the substance being assessed. Exposure is usually continuous.
Any medical study which follows a family of people through several generations.
(09 Oct 1997)
crossover study <statistics> A study that compares two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. Usually refers to a study in which the subject is switched from the experimental to the control procedure (or vice versa).
In the case of two treatments, a and b, half the subjects are randomly allocated to receive these in the order a, b and half to receive them in the order b, a.
A criticism of this design is that effects of the first treatment may carry over into the period when the second is given.
With this type of study, every patient serves as his or her own control.
(21 Jun 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • infection
    ¿µÇâ; Àü¿°º´
  • droplet infection
    (ÀÇ)ºñ¸» °¨¿°
  • focal infection
    º´¼Ò°¨¿°
  • infection
    (º´µ¶ÀÇ)°ø±âÀü¿°;°¨¿°(cf.CONTAFION)(µµ´öÀûÀ¸·Î)³ª»Û °¨È­(¿µÇâ);¿À¿°(CONTAMINATION)Àü¿°º´;°¨¿°Áõ
  • infection point
    º¯°îÁ¡
  • study
    °øºÎ,¼­Àç,Çаú,¹è¿ì´Ù,¿¬±¸ÇÏ´Ù
  • brown study
    ¸ÛÇÏ´Ï»ý°¢¿¡Àá±è
  • case study
    »ç·Ê¿¬±¸;ÄÉÀ̽º ½ºÅ͵ð M
  • desk study
    (¿µ)Ź»ó ¿¬±¸
  • feasibility study
    Ÿ´ç¼º Á¶»ç;¿¹ºñ Á¶»ç
  • field study
    =FIELDWORK
  • home study
    (Åë½Å ±³À°¿¡¼­ÀÇ)ÀÚÅà ÇнÀ;(¹Ì)(¾çºÎ¸ð·Î¼­ÀÇ ÀûºÎ¸¦ ¾Ë¾Æº¸´Â)°¡Á¤Á¶»ç
  • home study
    Åë½Å±³À°
  • nature study
    ÀÚ¿¬°øºÎ(²É »õ ±¤¼® ³¯¾¾µîÀÇ °üÂû,±¹¹ÎÇб³ÀÇ Çаú ''
  • study
    ½ÀÀÛ;½ÃÀÛ;¼­Àç;¿¬±¸½Ç;¾Ö¾¸
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á